Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
about
Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerEverolimus in the Treatment of Metastatic Breast CancerErbb2 is required for cardiac atrial electrical activity during developmentDesign and applications of bispecific heterodimers: molecular imaging and beyondSurvivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathwayHER2 in solid tumors: more than 10 years under the microscope; where are we now?The Therapeutic Challenge of Targeting HER2 in Endometrial CancerHER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.Matrine inhibited proliferation and increased apoptosis in human breast cancer MCF-7 cells via upregulation of Bax and downregulation of Bcl-2.p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm,Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Precision medicine and personalized breast cancer: combination pertuzumab therapy.The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.Precision treatment for cancer: role of prognostic and predictive markers.Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2.Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance.MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1.Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.Actionable gene-based classification toward precision medicine in gastric cancer.Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial.
P2860
Q26770482-62976EE1-7BC5-4AB4-B57A-D46D20886677Q26784920-398C3216-1AE8-4901-AA7D-9AA05864FFD7Q27348830-4DEAA3C4-496F-49D3-889F-98C20A980D75Q33732587-7F6DC102-39A3-4B6A-8961-6CBAED008FB3Q33827053-7C3F12E5-94A2-43FB-94FC-1573F73E7FF2Q34622404-99A749F2-B86E-46E3-B7C1-22C3F8CACC2AQ35211263-FA19CEDF-1207-43A7-9869-B161ABDBC073Q36064912-AC8B5E71-1F0C-42CF-A6D4-BD42F1357DF0Q36087126-E0E4D774-D84F-48B7-ACEC-AEE5E3BB7034Q36269777-553B3531-BD39-4163-9C7C-1B7608A56F74Q36464630-A561B4DF-20C3-4374-BF27-6706E22DDA9EQ36782465-3A831237-7F9D-4E30-B41E-3E3CC532D49BQ36910173-37050347-4C09-4A9A-9DCB-F5D2E958C8BFQ37109776-16657362-AD80-431F-82FE-038EB00C7651Q37496378-9E0E5F42-C05C-41C7-8C0F-876A6CA06C8BQ37534910-0DEFFB2D-B658-46F6-8132-669C39716223Q37650735-432D6CDA-6436-4DB3-8AF2-1FB90B11ABD5Q37687975-AF567682-95A9-4125-B44E-CFC36727B066Q37737145-1B9C5496-26FF-4386-A1FC-B5ED926EE36DQ38179024-E914A891-A439-42BA-B083-8A6C9AD23B34Q38457923-784A1A26-0DDC-4289-B40C-4283CD650041Q38717360-8AD50504-6889-4F6B-B038-8EC631C6C8F9Q38838851-07B50088-B351-4C59-BB8C-8E28D3F0A0FFQ38839786-16D94A35-94FD-4D14-A006-6DA0A470A930Q41915916-9209EBA4-1378-4878-8637-40ADE8EABDF6Q42109090-DCD476AF-4F86-4186-9535-29AC4ED81E87Q47113548-F7B2B69B-3A4B-407B-B792-D82BCAF4D47EQ47136161-070D782E-E43A-490D-82FF-57B3E7738899
P2860
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Overcoming resistance and rest ...... ed therapies in breast cancer.
@ast
Overcoming resistance and rest ...... ed therapies in breast cancer.
@en
type
label
Overcoming resistance and rest ...... ed therapies in breast cancer.
@ast
Overcoming resistance and rest ...... ed therapies in breast cancer.
@en
prefLabel
Overcoming resistance and rest ...... ed therapies in breast cancer.
@ast
Overcoming resistance and rest ...... ed therapies in breast cancer.
@en
P2093
P2860
P921
P356
P1433
P1476
Overcoming resistance and rest ...... ed therapies in breast cancer.
@en
P2093
B T Hennessy
M S N Mohd Sharial
P2860
P304
P356
10.1093/ANNONC/MDS200
P5008
P577
2012-08-02T00:00:00Z
2012-12-01T00:00:00Z